Abstract
Background: Congenital tooth agenesis (CTA) is a common developmental anomaly with complex genetic and molecular mechanisms. Previous studies have primarily focused on candidate gene mutations, often lacking a pan-omics perspective. Methods: This study integrates metabolomics, proteomics, microarray, and genomics with machine learning to identify biomarkers and elucidate disease mechanisms. A random forest-based classification achieved high AUC-ROC scores (0.95 for proteomics, 0.98 for metabolomics), validating the biomarker discovery framework. Results: Several biomarkers were identified in this study that enhance our understanding of CTA. Furthermore, our findings reveal a significant association between CTA and ecto-mesodermal diseases, which has not been extensively explored before. Notably, 24 dual-expression genes were expressed in both pre- and post-developmental stages, suggesting a regulatory role in tooth integrity, repair, and homeostasis. Metabolomics analysis revealed 28 upregulated and 17 downregulated metabolites uniquely associated with CTA. Key metabolic alterations involved nucleotide metabolism, purine metabolism, oxidative stress, and Wnt signaling. High-performing metabolites (AUC ≥ 0.90), including PEG n5 (0.99), PEG n6 (0.98), PEG-4 (0.97), PEG n7 (0.96), PEG n8 (0.95), caffeine (0.94), hydroxycaproic (0.91) and alpha-aspartylphenylalanine (0.90) demonstrated strong diagnostic potential. CTA patients showed 292 unique metabolites vs. 238 in controls, indicating metabolic pathway alterations. Proteomic analysis identified 76 upregulated and 33 downregulated genes, with key biomarkers [SERPINA1 (0.92), PZP (0.90), FGA (0.91), TLN1(0.94), FGB (0.95)] displaying AUC-ROC ≥ 0.90. Pan-omics fusion followed by STRING analysis identified 20 central hub genes strongly correlated with congenital tooth agenesis signaling. Conclusion: This study pioneers the systemic association of CTA with ecto-mesodermal diseases, revealing novel signatures, disrupted pathways, and therapeutic targets.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of the Institute of Science, Banaras Hindu University, India.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos